Protocol: CDISCPILOT01                                                                  Page  1 of 1 
Population: Efficacy 
Table 14-3.01 
Primary Endpoint Analysis: ADAS Cog (11) - Change from Baseline to Week 24 - LOCF 
 
 
[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline 
value as a covariate. 
[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable. 
[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple 
comparisons. 
Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas                  21:05 Monday, June 26, 2006 
 
Placebo 
 (N=79)  
Xanomeline 
 Low Dose 
 (N=81)  
Xanomeline 
 High Dose 
 (N=74)  
Baseline 
  n                                   79 
  81 
  74 
  Mean (SD)                           24.1 (12.19) 
  24.4 (12.92) 
  21.3 (11.74) 
  Median (Range)                      21.0 (5;61) 
  21.0 (5;57) 
  18.0 (3;57) 
Week 24 
  n                                   79 
  81 
  74 
  Mean (SD)                           26.7 (13.79) 
  26.4 (13.18) 
  22.8 (12.48) 
  Median (Range)                      24.0 (5;62) 
  25.0 (6;62) 
  20.0 (3;62) 
Change from Baseline 
  n                                   79 
  81 
  74 
  Mean (SD)                            2.5 (5.80) 
   2.0 (5.55) 
   1.5 (4.26) 
  Median (Range)                       2.0 (-11;16) 
   2.0 (-11;17) 
   1.0 (-7;13) 
 
  p-value(Dose Response) [1][2]      
 
  0.245 
 
  p-value(Xan - Placebo) [1][3]     
 
   0.569 
   0.233 
   Diff of LS Means (SE)            
 
-0.5 (0.82) 
-1.0 (0.84) 
   95% CI                           
 
(-2.1;1.1) 
(-2.7;0.7) 
 
  p-value(Xan High - Xan Low)[1][3] 
 
 
 
   0.520 
   Diff of LS Means (SE)            
 
 
-0.5 (0.84) 
   95% CI                           
 
 
(-2.2;1.1) 
 
